TNFSF13B and plasma cell myeloma: The antibody binds to the myeloma cell’s BCMA receptor to block BAFF and APRIL signaling while the auristatin component is released intracellularly via a lysosome-dependent mechanism causing cell cycle arrest at the G2/M checkpoint [127,128].